Senior Bioinformatician - Immunology
1 month ago
Oxfordshire
The Company has an ERAP1 inhibitor for immuno-oncology, currently in Phase I/II clinical trials. In addition, they have nominated a second ERAP1 inhibitor, expected to enter Phase I for autoimmune ...